Searched for: person:parkee01
Marginal Misses in Gamma-knife Radiosurgery for Meningiomas: Are Treatment Volume and Dose Adequate? [Meeting Abstract]
Sethi, R. A.; Rush, S. C.; Liu, S.; Huang, P.; Parker, E.; Donahue, B.; Narayana, A.; Golfinos, J.
ISI:000310542900701
ISSN: 0360-3016
CID: 204782
Impact of Histological Subtype on the Outcome of Breast Cancer Brain Metastases Patients Treated With Gamma-knife Radiosurgery [Meeting Abstract]
Hardee, M. E.; Hsu, H.; Parker, E. C.; Narayana, A.; Golfinos, J. G.; Formenti, S. C.
ISI:000310542900570
ISSN: 0360-3016
CID: 204842
Use of Vemurafenib, a BRAF Inhibitor Along With Radiation Therapy in Melanoma Brain Metastasis [Meeting Abstract]
Narayana, A.; Mathew, M.; Golfinos, J. G.; Parker, E. C.; Ott, P.; Pavlick, A. C.
ISI:000310542900765
ISSN: 0360-3016
CID: 204892
Ipitimumab in Melanoma With Limited Brain Metastasis Treated With Stereotactic Radiosurgery [Meeting Abstract]
Mathew, M.; Ott, P.; Pavlick, A. C.; Rush, S. C.; Donahue, B.; Golfinos, J. G.; Parker, E. C.; Huang, P.; Narayana, A.
ISI:000310542900759
ISSN: 0360-3016
CID: 204902
IPILIMUMAB IN MELANOMA WITH LIMITED BRAIN METASTASIS TREATED WITH STEREOTACTIC RADIOSURGERY [Meeting Abstract]
Mathew, Maya; Ott, Patrick; Rush, Stephen; Donahue, Bernadine; Pavlick, Anna; Golfinos, John; Parker, Erik; Huang, Paul; Narayana, Ashwatha
ISI:000310971300240
ISSN: 1522-8517
CID: 204952
USE OF MULTIVOXEL DSC-MRI PERFUSION DATA IN STEREOTACTIC-GUIDED GLIOMA SURGERY AND CORRELATION WITH TUMOR PATHOLOGY [Meeting Abstract]
Parker, Erik; Fatterpekar, Girish; Raz, Eytan; Narayana, Ashwatha; Johnson, Glyn; Placantonakis, Dimitris; Zagzag, David
ISI:000310971300496
ISSN: 1522-8517
CID: 204992
INTRINSIC ENHANCEMENT FROM THE NECROTIC COMPONENT OF RING-ENHANCING LESIONS: A KEY IMAGING FEATURE TO DISTINGUISH NECROTIC TUMORS FROM ABSCESSES [Meeting Abstract]
Fatterpekar, Girish; Raz, Eytan; Knopp, Edmond; Gruber, Michael; Parker, Erik; Golfinos, John; Zagzag, David
ISI:000310971300495
ISSN: 1522-8517
CID: 205012
VEMURAFENIB AND RADIATION THERAPY IN MELANOMA BRAIN METASTASIS [Meeting Abstract]
Narayana, Ashwatha; Mathew, Maya; Kannan, Rajni; Madden, Kathleen; Golfinos, John; Parker, Erik; Ott, Patrick; Pavlick, Anna
ISI:000310971300199
ISSN: 1522-8517
CID: 205042
Multicentric Castleman's Disease of the Central Nervous System : Evaluation with Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging
Pawar, R V; Fatterpekar, G M; Zagzag, D; Parker, E C; Narayana, A
PMID: 21837500
ISSN: 1869-1447
CID: 178315
Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site
Ma, Michelle W; Qian, Meng; Lackaye, Daniel J; Berman, Russell S; Shapiro, Richard L; Pavlick, Anna C; Golfinos, John G; Parker, Erik C; Darvishian, Farbod; Hernando, Eva; Shao, Yongzhao; Osman, Iman
Melanoma brain metastasis that develops as the isolated first visceral site challenges the current paradigm of tumor progression in which brain metastasis is regarded as the final stage. Here we test the hypothesis that melanoma patients who develop brain metastasis as the isolated first visceral site have distinct clinicopathological features at the time of primary melanoma diagnosis. Cutaneous melanoma patients enrolled in 2 prospectively collected databases were studied (Cohort 1: 1972-1982, Cohort 2: 2002-2009). Patients who developed brain metastasis as isolated first visceral site were compared with (1) all other patients, (2) patients who developed visceral metastasis: extracranial only or extracranial and brain, and (3) patients who progressed to other isolated visceral sites first. Two hundred seven of 2280 (9.1%) patients developed brain metastasis (median follow-up, 5.2 y). Seventy-four of 207 (35.7%) brain metastasis patients progressed to brain metastasis as the isolated first visceral site. These patients presented with primaries that were thinner and had no mitosis compared with all other visceral metastasis patients (Fisher's combined P = .02, .05, respectively), and there was a significant difference in American Joint Committee on Cancer stage distribution at initial melanoma diagnosis (combined P = .02). Post-visceral metastasis survival, however, was shorter in patients with brain metastasis as isolated first visceral site than in patients with visceral metastasis: extracranial and brain (combined P = .03). Brain metastasis as isolated first visceral site is a distinct clinicopathological entity. Studies are needed to better understand the biological factors driving this phenotype at the time of primary melanoma diagnosis and to determine its clinical implications.
PMCID:3379800
PMID: 22561799
ISSN: 1522-8517
CID: 169477